These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 36605427)

  • 1. Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma.
    Li Y; Ji Y; Shen L; Yin X; Huang T; Deng B; Guo H; Wu Y; Chen Y
    Front Oncol; 2022; 12():1015302. PubMed ID: 36605427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma.
    Zhang Z; Yang L; Wang D; Ruan Y; Zhang J; Zhao L; Yang L; Lou C
    Ther Adv Med Oncol; 2023; 15():17588359231169981. PubMed ID: 37188111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Efficacy of Taxol Plus Platinum (TP) Chemotherapy Combined with Delayed Administration of PD-1 Inhibitors in Patients with Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study.
    Shen L; Chen Z; Zhang Z; Wu Y; Ren Y; Li Y; Li Y; Yin X; Han F; Chen Y
    Drug Des Devel Ther; 2024; 18():2761-2773. PubMed ID: 38979399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors' combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis.
    Li D; Tang L; Hu J; Cao X; He Y
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):933-939. PubMed ID: 35751682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis.
    Zhao J; Zhang S; Guo X; Li C; Yang B; Qu X; Wang S
    BMC Cancer; 2023 Dec; 23(1):1221. PubMed ID: 38082441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
    Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety evaluation of frontline immunotherapy combinations in advanced esophageal squamous cell carcinoma: a network meta-analysis highlighting the value of PD-L1 expression positivity scores.
    Chen W; Cao K; Zhang L; Zhao X; Chen B; Li W; Shang R; Sun L; Jiang Z; Wang J; Xue W
    Front Immunol; 2024; 15():1414753. PubMed ID: 39050848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching.
    Jing SW; Zhai C; Zhang W; He M; Liu QY; Yao JF; Wang R; Tian ZQ; Wang J; Liu JF
    Front Immunol; 2022; 13():970534. PubMed ID: 36275724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of first-line chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis.
    Ma SX; Zhou T; Huang Y; Yang YP; Zhan JH; Zhang YX; Zhang ZH; Zhao YY; Fang WF; Ma YX; Chen LK; Zhao HY; Zhang L
    Ann Transl Med; 2018 Jun; 6(11):201. PubMed ID: 30023364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma.
    Yang Y; Li H; Chen X; Qin J; Li Y; Shen Y; Zhang R; Kang X; Wang Z; Zheng Q; Luo P; Li Y; He J
    Thorac Cancer; 2023 Mar; 14(7):700-708. PubMed ID: 36788648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
    Lu Y; Wang W; Wang F
    Front Immunol; 2023; 14():1171671. PubMed ID: 37205107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies.
    Wang T; Yu J; Liu M; Chen Y; Zhu C; Lu L; Wang M; Min L; Liu X; Zhang X; Gubat JA; Chen Y
    Drug Des Devel Ther; 2019; 13():539-553. PubMed ID: 30787595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in the second-line treatment of advanced esophageal squamous cell carcinoma: a meta-analysis and systematic review.
    Zhu K; Chen H; Xu C; Chen D; Jin Z; Ren S; Witharana P; Chen B; Shen J
    J Thorac Dis; 2023 Mar; 15(3):1186-1195. PubMed ID: 37065572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors combined with or without radio(chemo)therapy for locally advanced or recurrent/metastatic esophageal squamous cell carcinoma.
    Zhao XH; Gao HM; Wen JY; Wang HS; Wu LY; Song CY; Deng WZ; Zhu SC; Shen WB
    Discov Oncol; 2023 Sep; 14(1):165. PubMed ID: 37665394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors
    Liu S; Dou L; Li S
    Therap Adv Gastroenterol; 2024; 17():17562848241233134. PubMed ID: 38425370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
    Poulose JV; Kainickal CT
    World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Chen R; Hou X; Yang L; Zhao D
    Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal first-line treatment for platinum-eligible metastatic urothelial carcinoma: Comparison of chemo-immunotherapy, immunotherapy, and chemotherapy- A systematic review and meta-analysis.
    Li H; Ni M; Xue C; Li L; Huang R; Yang W; Hu A; An X; Shi Y
    Clin Immunol; 2022 Mar; 236():108927. PubMed ID: 35031491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.